



# ADVANCING SCIENCE

in the Fast-Growing Pharmaceutical and Biotechnology Sector

CIBC Eastern Institutional Investor Conference | September 21, 2022

# DISCLAIMER

Certain statements made in this presentation, including responses to questions, may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.

For additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, please consult the MD&A, the Risk Factors section of the Annual Information Form and DRI Healthcare Trust's other filings with Canadian securities regulators. DRI Healthcare Trust does not undertake to update any forward-looking statements; such statements speak only as of the date made.

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under IFRS and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of DRI Healthcare Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS.

All dollar figures in this presentation are stated in US dollars.

# ABOUT DRI HEALTHCARE TRUST


**DRI provides lower-risk exposure to the fast-growing, global pharmaceutical and biotech industry through the ownership and acquisition of pharmaceutical royalties**

- Managed by DRI Capital Inc., the pioneer in healthcare royalty monetization with a 33-year history
- IPO in February 2021  
(TSX: **DHT.UN**; **DHT.U**)

# KEY SUCCESS FACTORS

- Pioneer in the industry with a 33-year track record of success
  - *Strong track record of deal execution across a variety of counterparties and therapeutic areas*
- Deep institutional knowledge and market intelligence tools based on thousands of evaluated transactions
  - *Proprietary database and extensive industry relationships*
- Seasoned and highly specialized professional investing team
  - *Science backgrounds and advanced academic degrees*

# OUR BUSINESS MODEL



# FOCUSED GROWTH IN ATTRACTIVE MARKET NICHE

**Growth-focused  
accretive** small to  
mid-sized  
transactions

- Medically necessary, market leading products with strong growth potential
- Benefit from strong and long-lasting intellectual property
- Developed or marketed by industry leading, high-quality life sciences companies

# OUR KEY PRIORITIES

## **Grow asset base**

Execute on strong pipeline to acquire royalties on high quality assets that meet our investment criteria

## **Accretive growth**

Focus on long-term, sustainable growth in top line royalty receipts and cash flow per unit

## **Unitholder returns**

Continue focus on unitholder returns and appropriate distribution policy